Analytical Data
-
Gene name
HLA-A*24:02&B2M&NY-ESO-1(LLMWITQCF) Monomer
- Application
-
Alternative Names
HLA-A*2402 & B2M & NY-ESO-1 (LLMWITQCF)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59600.1 (G25-T305)&P61769
-
Expression Region
AAA59600.1 (G25-T305)&P61769 (I21-M119)&LLMWITQCF
-
Molecular Weight
38-42 kDa and 14 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of HLA-A*24:02, a specific human leukocyte antigen, alongside beta-2-microglobulin (B2M) and the tumor-associated antigen NY-ESO-1, is crucial for advancing our understanding of immune responses in cancer immunotherapy. HLA-A*24:02 is prevalent in certain populations, making it a significant focus in developing personalized therapeutic vaccines and T-cell therapies. NY-ESO-1 is a cancer-testis antigen expressed in various tumors, but not in normal tissues, making it an attractive target for tumor immunotherapy. The specific peptide LLMWITQCF binds effectively to HLA-A*24:02 and elicits potent T-cell responses, which is essential for generating an effective anti-tumor immune response. Research involving the recombinant monomeric protein of HLA-A*24:02, complexed with B2M and the NY-ESO-1 peptide, aims to elucidate its structural and functional properties. This could lead to enhanced understanding of T-cell receptor interactions and the design of more effective immunotherapeutic strategies. The recombinant protein serves as a valuable tool for monitoring immune responses in clinical settings and may aid in the development of vaccines aimed at eliciting strong and specific anti-tumor immunity in HLA-A*24:02-positive patients. Ultimately, this line of research holds potential for improving cancer treatment and patient outcomes in a diverse array of malignancies.
